Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial - 31/03/16

Doi : 10.1016/S1470-2045(15)00614-2 
Dong-Wan Kim, MD a, Ranee Mehra, MD b, Daniel S W Tan, MD c, Enriqueta Felip, MD d, Laura Q M Chow, MD e, D Ross Camidge, ProfMD f, Johan Vansteenkiste, ProfMD g, Sunil Sharma, ProfMD h, Tommaso De Pas, MD i, Gregory J Riely, MD j, Benjamin J Solomon, MBBS k, Jürgen Wolf, ProfMD l, Michael Thomas, ProfMD m, Martin Schuler, ProfMD n, Geoffrey Liu, MD o, Armando Santoro, ProfMD p, Santosh Sutradhar, PhD q, Siyu Li, PhD q, Tomasz Szczudlo, MD q, Alejandro Yovine, MD r, Alice T Shaw, DrMD s,
a Seoul National University Hospital, Seoul, Korea 
b Fox Chase Cancer Center, Philadelphia, PA, USA 
c National Cancer Center, Singapore, Singapore 
d Vall d’Hebron University, Barcelona, Spain 
e University of Washington, Seattle, WA, USA 
f University of Colorado, Denver, CO, USA 
g University Hospital KU Leuven, Leuven, Belgium 
h Huntsman Cancer Institute, Salt Lake City, UT, USA 
i Istituto Europeo di Oncologia, Milan, Italy 
j Memorial Sloan Kettering Cancer Center, New York, NY, USA 
k Peter MacCallum Cancer Center, Melbourne, VIC, Australia 
l Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany 
m Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany 
n University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany 
o Princess Margaret Cancer Center, Toronto, ON, Canada 
p IRCCS Institute Clinico Humanitas, Milan, Italy 
q Novartis Pharma, East Hanover, NJ, USA 
r Novartis Pharma AG, Basel, Switzerland 
s Massachusetts General Hospital, Boston, MA, USA 

*Correspondence to: Dr Alice T Shaw, Massachusetts General Hospital, Boston, MA 02114, USAMassachusetts General HospitalBostonMA02114USA



ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably develops, often with progression in the brain. Ceritinib is a more potent ALK inhibitor than crizotinib in vitro, crosses the blood–brain barrier in vivo, and shows clinical responses in patients with crizotinib-resistant disease. We aimed to assess whole-body activity of ceritinib in both ALK inhibitor-pretreated and ALK inhibitor-naive patients with ALK-rearranged NSCLC.


ASCEND-1 was an open-label, phase 1 trial that recruited patients from 20 academic hospitals or cancer centres in 11 countries in Europe, North America, and Asia-Pacific. Eligible patients were aged 18 years or older with ALK-rearranged locally advanced or metastatic cancer that had progressed despite standard therapy (or for which no effective standard therapy existed), who had at least one measurable lesion at baseline. The primary objective (to determine the maximum tolerated dose) has been reported previously. This updated analysis includes all patients with ALK-rearranged NSCLC given oral ceritinib at the recommended dose of 750 mg/day in the dose-escalation and expansion phases. Here we report the secondary outcomes of overall response, duration of response, and progression-free survival, analysed in all patients who received at least one 750 mg dose of ceritinib. Exploratory analyses included retrospective analysis of intracranial activity by independent neuroradiologists, in patients with untreated or locally treated neurologically stable brain metastases at baseline. Safety was assessed in all patients who received at least one dose of ceritinib. This study is no longer recruiting patients; however, treatment and follow-up are ongoing. This study is registered with ClinicalTrials.gov, number NCT01283516.


Between Jan 24, 2011, and July 31, 2013, 255 patients were enrolled and received at least one dose of ceritinib 750 mg/day, of whom 246 had ALK-rearranged NSCLC. At data cutoff (April 14, 2014), median follow-up was 11·1 months (IQR 6·7–15·2) and 147 (60%) patients had discontinued treatment, 98 (40%) as a result of disease progression. An overall response was reported in 60 (72% [95% CI 61–82]) of 83 ALK inhibitor-naive patients and 92 (56% [49–64]) of 163 ALK inhibitor-pretreated patients. Median duration of response was 17·0 months (95% CI 11·3–non-estimable [NE]) in ALK inhibitor-naive patients and 8·3 months (6·8–9·7) in ALK inhibitor-pretreated patients. Median progression-free survival was 18·4 months (95% CI 11·1–NE) in ALK inhibitor-naive patients and 6·9 months (5·6–8·7) in ALK inhibitor-pretreated patients. Of 94 patients with retrospectively confirmed brain metastases and at least one post-baseline MRI or CT tumour assessment, intracranial disease control was reported in 15 (79% [95% CI 54–94]) of 19 ALK inhibitor-naive patients and in 49 (65% [54–76]) of 75 ALK inhibitor-pretreated patients. Of these 94 patients, 11 had measurable brain lesions and no previous radiotherapy to the brain, six of whom achieved a partial intracranial response. Serious adverse events were recorded in 117 (48%) of 246 patients. The most common grade 3–4 laboratory abnormalities were increased alanine aminotransferase (73 [30%] patients) and increased aspartate aminotransferase (25 [10%]). The most common grade 3–4 non-laboratory adverse events were diarrhoea and nausea, both of which occurred in 15 (6%) patients. Two on-treatment deaths during the study were deemed to be related to study drug by the investigators, one due to interstitial lung disease and one as a result of multiorgan failure that occurred in the context of infection and ischaemic hepatitis.


The durable whole-body responses reported, together with the intracranial activity, support a clinical benefit for treatment with ceritinib in patients with ALK-rearranged NSCLC who have received crizotinib, or as an alternative to crizotinib. A confirmatory phase 2 clinical trial is ongoing to assess ceritinib activity in patients with ALK-rearranged NSCLC and brain or leptomeningeal metastases.


Novartis Pharmaceuticals Corporation.

Le texte complet de cet article est disponible en PDF.


© 2016  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

    Export citations

  • Fichier

  • Contenu

Vol 17 - N° 4

P. 452-463 - avril 2016 Retour au numéro
Article précédent Article précédent
  • Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study
  • Brian O’Sullivan, Shao Hui Huang, Jie Su, Adam S Garden, Erich M Sturgis, Kristina Dahlstrom, Nancy Lee, Nadeem Riaz, Xin Pei, Shlomo A Koyfman, David Adelstein, Brian B Burkey, Jeppe Friborg, Claus A Kristensen, Anita B Gothelf, Frank Hoebers, Bernd Kremer, Ernst-Jan Speel, Daniel W Bowles, David Raben, Sana D Karam, Eugene Yu, Wei Xu
| Article suivant Article suivant
  • Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial
  • Shafak Aluwini, Floris Pos, Erik Schimmel, Stijn Krol, Peter Paul van der Toorn, Hanja de Jager, Wendimagegn Ghidey Alemayehu, Wilma Heemsbergen, Ben Heijmen, Luca Incrocci

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.